Menu
Pancreatic cancer
...is the least funded cancer in terms of research. Despite causing enormous mortality, pancreatic cancer receives (on a mortality basis) much less funding for research.
Click Here to Help
Pancreatic cancer
...is the most aggressive of the major cancers, has the highest mortality rate, and the LEAST funded. There are no early detection tests.
Click Here to Help
Pancreatic cancer
Pancreatic cancer has the lowest survival rate of all cancers. This year, an estimated 56,770 adults (29,940 men and 26,830 women) in the United States will be diagnosed.
Click Here to Help
Walk, Run, or Choose your own!
Set up a fundraising page to start now! We will be in touch, and be with you all the way!
Click Here to Start

CONFRONTING PANCREATIC CANCER

Join us in our effort to fight pancreatic cancer. Donations allow for timely delivery of critical information about pancreatic cancer.

PANCREATIC CANCER SCREENING TESTS AND MARKERS

Presently, there is no agreed upon screening test to aid in the identification or earlier diagnosis of pancreatic cancer (ductal adenocarcinoma of the pancreas) for the general population. There is the beginning of the establishment of protocols involving periodic testing procedures at certain academic institutions to follow persons at high risk for pancreatic cancer, but these measures have not been well studied yet.

The best known of the blood markers for pancreatic cancer is CA19-9, a “carbohydrate associated antigen” also known as a sialylated Lewis (a) antigen. This marker is somewhat uneven in the diagnosis of pancreatic cancer, but can be quite elevated in those with pancreatic cancer. Approximately 10% of Caucasians lack the Lewis antigen, so in them the CA19-9 is not expressed. Currently, some oncologists appear to feel that the best use of the CA19-9 marker is as a guide to follow the disease and treatment process in a given individual patient.

There are mutations in specific DNA genes that are found commonly in pancreatic cancer. Some of these well-known genes are k-ras, p53 and p16. Because of the development of genetic micro-array tools (that allow for a huge number of tests all at once), in the past decade there has been a remarkable increase in research looking for genetic fingerprints to aid in the screening for and earlier diagnosis of pancreatic cancer. And although there has been a big increase in knowledge about DNA mutations and specific genes involved in pancreatic cancer, thus far this has not translated (yet) into screening tests or a diagnostic marker for pancreatic cancer. However, it remains an area of great interest.

A related area is represented by the many proteins that emanate from genetic instruction. The whole of this array of proteins is called the proteome. There has been considerable research in this area to try to detect reliable protein patterns in pancreatic cancer that will allow for screening or earlier diagnosis. Thus far, much has been learned but no universally recognized markers have been established through the study of protein patterns.

Many other agents have been studied as screening and diagnostic markers without much success. Some of these include cell surface associated mucins (MUC), carcinoembryonic antigen (CEA), and heat shock proteins (HSP).

Apart from the genome and proteome, another area of great recent research interest in screening and diagnostic markers for pancreatic cancer has been in that of MicroRNAs. First characterized in the 1990s, MiRNAs are small (22 nucleotide) non-coding RNA molecules involved in genetic regulation. There have been many recent intriguing study results looking at patterns of various MiRNA types in pancreatic cancer.

Researchers have looked at many tissues and access points to study these potential markers including in stool, pancreatic juice, saliva and blood.

The amount of research into the area of finding a means of screening for or providing for the earlier diagnosis of pancreatic cancer has increased dramatically in the past decade. It is a promising arena, as finding pancreatic cancer earlier would likely enable many more patients to avail themselves of surgery, for example. Much more is known than in the past. And is seems likely that this big knowledge will eventually lead to practical results. But despite gains we are not there yet. Some of the more recent developments in this area have been discussed in detail in our Pancreatica Blog.

ABSTRACTS:

The following are descriptions of titles of abstracts of medical journal articles that may be interesting or useful to those who are interested in further information about this topic.These abstracts can be searched Here.

    • 15-Nov-16 – Blood mRNA diagnostic pattern in cancer of the pancreas
    • 1-Oct-16 – MicroRNAs in saliva and serum as pancreatic cancer markers ?
    • 16-Aug-16 – mRNAs as biomarkers for adenocarcinoma of the pancreas
    • 1-Feb-16 – Proteoglycan glypican-1 as found in serum exosomes as a marker for cancer of the pancreas
    • 1-Aug-15 – blood component ratios as survivor markers of pancreatic cancer surgery
    • 19-Jun-15 – chemokine receptor CXCR4 as a biomarker for pancreatic cancer
    • 1-Aug-13 – Insulin-like Growth Factor Marker in Gemcitabine plus a Monoclonal Antibody Inhibitor of IGF-1 Receptor
    • 1-Aug-13 – Protein levels from S100 Genes as Marker for Post-surgical Treatment in Pancreatic Cancer
    • 12-Mar-13 – CA19-9 and a MicroRNA for the Diagnosis of Pancreatic cancer
    • 1-Jan-13 – Markers of Inflammation, Liver Function Tests, CA19-9, and CEA for Pancreatic Cancer
  • 21-Jan-14 – C-Reactve Protein and Ferritin as Prognostic Markers for Cancer of the Pancreas
  • 1-Dec-13 – Gene Methylation Assay for Early Diagnosis of Cancer of the Pancreas
  • 1-Dec-13 – MicroRNA-222 and Increased Cell Proliferation in Cancer of the Pancreas
  • 7-Nov-13 – CRP Levels for Prognosis in Adenocarcinoma of the Pancreas
  • 22-Oct-13 -The CA-125 Biomarker as a Predictor of Surgical Need in Cancer of the Pancreas
  • 2-Oct-13 – Panel Array for the  Diagnosis of Cancer of the Pancreas
  • 1-Jan-12 – MIRNA and the Diagnosis of Pancreatic Cancer
  • 1-Dec-12 – MiRNA-143 in Metastatic Pancreatic cancer
  • 1-Aug-11 – Smad4 Marker Association with Chemoradiation Response
  • 1-Apr-09 – Plasma K-ras as a Potential Treatment Marker for Pancreatic cancer
  • 15-Sep-03 – TS Marker Associated with Positive Effect of 5-FU
  • 1-Sep-03 – Tumor Marker in the Determination of Surgery Possibility for Pancreatic Cancer
  • 1-Apr-03 – Genetic Make-up of Pancreatic Cancer

 

Join the fight against pancreatic cancer!

Set up a fundraising page to join the fight! We will be in touch, and be with you all the way!

Our science board is composed of:

James Abbruzzese, MD Chief, Medical Oncology Duke University

Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany

Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University

Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center

Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco


 

Walk, Run, or Choose your own!

Set up a fundraising page to join the fight against pancreatic cancer. We will be in touch, and be with you all the way!

Sign up for the latest news about pancreatic cancer, ways to help, and more!

You have likely found us either because you have pancreatic cancer, or care about someone who does.

Our Philosophy About Pancreatic Cancer


Pancreatic cancer is a serious disease. Taking an aggressive rational stance at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for survival.

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.

Genetic Testing for Pancreatic Cancer

PROPOSED: Every newly diagnosed person with pancreatic cancer (ductal adenocarcinoma of the pancreas) should receive genetic screening prior to beginning treatment – to test for germline genetic mutations in the homologous recombination DNA repair pathway, including genes such as BRCA1, BRCA2, PALB2, and others. These results, in from 12% to 17% of pancreatic cancer patients, suggest that treatment that includes DNA cross-linking agents such as platinum compounds or PARP inhibitors may be superior to standard best practices therapy.


OFFER: Color Genomics offers a 30-gene cancer panel for $224 (normally $249) when the Promotion Code “PANCREATIC” is entered at checkout (price will reduce upon entering this code). This is a physician-ordered saliva kit. Click Here for more information

RATIONALE: The age of precision medicine in pancreatic cancer is approaching … [MORE]

Check out the Suzanne Wright Foundation

CodePurpleNow is their campaign inspired by Suzanne Wright and her fight against pancreatic cancer. During her lifetime, Suzanne dedicated herself to the most vulnerable among us. After her diagnosis, she made it her mission to fight pancreatic cancer with that same determination. More Here

Speak with a Survivor:

Call 1-800-433-0464 for a free service that will place you in contact with a fellow survivor, or to volunteer to contact someone more recently diagnosed.


Pancreatic Cancer Blog

One of the observations that physicians often made when the standard of care treatment typically consisted of the chemotherapy drug agent of gemcitabine alone, was that many patients with pancreatic cancer (ductal adenocarcinoma of the pancreas) seemed to feel better after the initiation of treatment… More Here

 

Best of the Blog

© 2019 Pancreatica. All rights reserved | Privacy Policy
312 Fountain Avenue, Pacific Grove, California 93950   |   Phone: (831) 658-0600   |   Fax: (831) 658-0518  |  participate@tofightcancer.com

Dedicate your birthday to fight pancreatic cancer or simply set up a page to honor a loved one.